Results

1–10 of 16 results for PDS

5-Year Outcomes in nAMD Patients Enrolled in the Archway Study and Treated With the PDS
John W. Kitchens, MD
Annual Meeting Talks
2025
Impact of PDS in Study Eyes vs Anti-VEGF Injections in Fellow Eyes in Pagoda Trial Patients With BilateralDiabetic Macular Edema (DME)
Jordan M. Graff, MD, FACS
Annual Meeting Talks
2025
Port Delivery System with Ranibizumab PDS for Continuous Treatment in DME and DR Additional Results from the Phase 3 Pagoda and Pavilion Trials
Dennis M. Marcus, MD
Annual Meeting Talks
2023
Expert Panel:PDS
Robert A. Mittra, MD, FASRS
Dante Joseph Pieramici, MD
Aleksandra V. Rachitskaya, MD, FASRS
Margaret A. Chang, MD, MS
Carl C. Awh, MD, FASRS
Annual Meeting Talks
2024
Key Surgical Pearls for the Prevention of Conjunctival Complications Following the Port Delivery System With Ranibizumab (PDS) Implant Insertion Procedure
On Demand Cases, Courses, and Papers
2022
Analysis of Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) in Patients With nAMD
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2021
Key Pearls of Conjunctival and Tenon’s Capsule Handling During the Implant Insertion Procedure for the Port Delivery System With Ranibizumab (PDS)
Veeral S. Sheth, MD, MBA, FASRS, FACS
Annual Meeting Talks
2021
Key Pearls of the Refill-Exchange Procedure for the Port Delivery System With Ranibizumab (PDS)
Jordan M. Graff, MD, FACS
Annual Meeting Talks
2021
Assessment of Central Subfield Thickness Fluctuations and Impact on Vision in Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS)
Chirag D. Jhaveri, MD, FASRS
Annual Meeting Talks
2021
Updated Safety and Efficacy Results From the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) for Neovascular AMD
Carl C. Awh, MD, FASRS
Annual Meeting Talks
2021